Clarifying a difficult diagnosis
Advanced biomarker analysis to detect invasive fungal infections
For immunosuppressed patients with nonspecific symptoms due to invasive fungal infections (IFI), diagnosis remains a challenge. Limitations of traditional laboratory testing often result in delayed diagnosis, which is associated with high mortality rates.
Fungal biomarker detection, used in conjunction with conventional testing methods, can overcome traditional laboratory limitations to make a presumptive diagnosis of fungal infection prior to symptom progression.
Mayo Clinic Laboratories offers an FDA-cleared and CE-marked rapid invitro diagnostics screening test for IFI caused by various fungi, including Aspergillus species, Fusarium species, Candida species, and Pneumocystis jirovecii, among others.
Note: When positive, repeat testing on a new sample (collected in 3–4 days) is recommended, as serially positive samples are associated with a higher diagnostic odds ratio for invasive fungal infection compared to a single positive result.
Increased confidence through superior quality measures
Mayo Clinic Laboratories’ ongoing focus on high-quality assurance is reinforced through the design and utilization of a dedicated, state-of-the-art testing room. This room features a positive pressure airflow to prevent outside air from entering the room, and HEPA filled instrumentation, which enables controls and prevents contamination. Each test request receives a single, dedicated serum vial, enabling confidence that a positive result is not due to a false positive or contamination event.
Recommended laboratory test pairings frequently used in conjunction with BDG testing
FGEN | Fungal Culture, Routine
FS | Fungal Smear, Varies
Additional test offerings
SHSTO | Histoplasma Antibody, Serum